💊 Syndax Plunges on FDA Delay, Anavex Soars on Positive Alzheimer's Trial, Exact Sciences Falls | Biotech Sector Insights
Gilead Sciences is making a $30 million milestone payment to Compugen, following FDA clearance for an investigational new drug application for COM503. This development enhances Gilead's oncology portfolio with a potential first-in-class anti-IL-18 binding protein antibody.
Welcome to the MarketReader Minute.
Below are AI-generated insights on moves in the health care/biotechnology sector, powered by MarketReader technology.
Monday, July 29
IBB [+0.3%]
The iShares Biotechnology ETF (IBB) has seen a price increase of 0.3% since Friday's market close. Key contributors to this performance include AMGN, VRTX, GILD, MRNA, and ILMN, all of which posted positive returns. Notably, Gilead Sciences is making a $30 million milestone payment to Compugen, following FDA clearance for an investigational new drug application for COM503. This development enhances Gilead's oncology portfolio with a potential first-in-class anti-IL-18 binding protein antibody and paves the way for Compugen to initiate a Phase 1 trial in solid tumors expected to commence in Q4. Additionally, the Russell 2000 Index has increased by 0.89%, reflecting a strong historical correlation with IBB.